Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2012 | 05:26am CEST
   By Rumman Ahmed 
 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
02:42p BRISTOL-MYERS SQUIBB COMPANY (OTCMKT : BMYMP) Files An 8-K Results of Operations..
02:28p BRISTOL MYERS SQUIBB CO : Results of Operations and Financial Condition, Financi..
02:01p BRISTOL MYERS SQUIBB : to Take Part in Deutsche Bank Annual Health Care Conferen..
01:30p BRISTOL MYERS SQUIBB : Myers tops Street 1Q forecasts
01:00p BRISTOL MYERS SQUIBB : Reports First Quarter Financial Results
04/25 BRISTOL MYERS SQUIBB : Reduces Environmental Impact Across the Globe
04/25 BRISTOL MYERS SQUIBB : Transgene and Bristol-Myers Squibb Announce Clinical Rese..
04/24 BRISTOL MYERS SQUIBB : Supreme Court - Argument Schedule
04/22 BRISTOL MYERS SQUIBB : BMS-986036 (Pegylated FGF21) Shows Consistent Improvement..
04/21 BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion Recommending Approval of O..
More news
Sector news : Pharmaceuticals - NEC
10:10aDJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue -- Update
09:41aDJASTRAZENECA : Correction to AstraZeneca Profit Drops on Decline in Blockbuster-D..
09:26aDJBAYER : First-Quarter Net Profit Up 38% at EUR2.08 Billion -- Update
08:48aDJGLAXOSMITHKLINE : New Glaxo CEO Seeks Tighter Drug Focus -- WSJ
08:45aDJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07:00a Bristol-Myers Squibb beats by $0.11, beats on revenue
04/26 Notable earnings before Thursday?s open
04/26 The Best Of The Blue Chips (And The Worst)
04/26 Sirtex Trial Miss Means Beads Could Stay As Back-Up
04/25 BIOGEN JUMPS ON Q1 RESULTS : Analysis
Advertisement
Financials ($)
Sales 2017 19 748 M
EBIT 2017 5 201 M
Net income 2017 4 482 M
Finance 2017 393 M
Yield 2017 3,03%
P/E ratio 2017 20,01
P/E ratio 2018 18,26
EV / Sales 2017 4,47x
EV / Sales 2018 4,28x
Capitalization 88 586 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 55,8 $
Spread / Average Target 3,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-7.99%88 586
JOHNSON & JOHNSON7.20%334 822
ROCHE HOLDING LTD.10.83%223 653
PFIZER INC.3.94%201 581
NOVARTIS AG2.77%201 384
MERCK & CO., INC.6.51%171 894
More Results